IP Library Granted Patent US 9,644,224
Granted Patent B2
US 9,644,224 · App. 12/965,714 · Granted May 9, 2017

Methods for cyclizing synthetic polymers

Inventor: Todd M. Kinsella (Redwood City, CA)
Assignee: RIGEL PHARMACEUTICALS, INC.
C12P19/34C12N15/10C12P21/02A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,644,224
App. No.
12/965,714
Granted
May 9, 2017
Kind
B2
Abstract

The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D 1 -X (n) -D 2 , where D 1 is a first catalytic domain of an intein; D 2 is a second catalytic domain of an intein; where the second catalytic domain has at its N-terminus a first reactive site for the intein; and X (n) is a polymer of a number n of monomer X, where the polymer N-terminus has a second reactive site for the intein. D 1 -X (n) -D 2 compounds autocatalytically cyclize the X (n) polymer to produce a cyclic polymer. The invention finds use in a variety of drug discovery, clinical and therapeutic applications.

Claims (15)

1. A method for making a cyclic polymer, comprising:

incubating a compound of the structure:

D 1 -X (n) -D 2

wherein D 1 is a first catalytic domain of an intein;

wherein X (n) is a polymer comprising n residues of a monomer X, n is at least 2, the polymer is not genetically encodable and is not made by a cell, and the polymer has a first reactive site for said intein at its N-terminus; and

wherein D 2 is a second catalytic domain of an intein, having at its N-terminus a second reactive site for said intein;

under intein reaction conditions to produce said cyclic polymer.

2. The method of claim 1 , wherein said incubating includes changing the temperature of said compound.

3. The method of claim 1 , wherein said synthetic polymer comprises at least one non-naturally occurring monomer.

4. The method of claim 1 , wherein said synthetic polymer comprises at least one amino acid monomer.

5. The method of claim 1 , wherein said synthetic polymer comprises at least one nucleotide monomer.

6. The compound of claim 1 , wherein D 1 , X (n) , and D 2 are joined by peptide bonds.

7. The compound of claim 1 , wherein n is at least 4.

8. The compound of claim 1 , wherein said monomers are amino acid monomers.

9. The compound of claim 1 , wherein said monomers are nucleotide monomers.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2011
From: KINSELLA, TODD M.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 026128/0672 →
Continuity (3)
Division 11136806 · May 24, 2005
Provisional Application 60574238 · May 24, 2004
Related Publication 20110087002A1 · Apr 14, 2011